Been folllowing this "Discussion Topic" for awhile but this is my first post here.
I found this video regrading recent changes to daily ADA testing guidelines very interesting.
http://www.medscape.com/viewarticle/778690
What impact would Afrezza have on the number of daily tests/strip? I would suspect far fewer would be required. Less strips = less comparative cost.
Also, (just speculation) I wonder if the large pre-market buy today had anything to do with last week's U.S. approval of the bionic eye? I understand that there is no connection between the two, other than Al.
blabla
